評(píng)論
打印
According to a report by Gizmodo, the United States' Food and Drug Administration
Gizmodo的一篇報(bào)道稱(chēng)，美國(guó)食品藥品監(jiān)督管理局
published a list of pharmaceutical companies that it accuses of impeding the development of generic drugs.
公布一系列制藥公司名單，這些公司被指控妨礙非專(zhuān)利藥發(fā)展。
The list, released on Thursday, include big names like Novartis, GlaxoSmithKline, Pfizer, and Valeant Pharmaceuticals
該名單發(fā)表于周四，其中包括很多大公司，比如諾華公司、葛蘭素史克、輝瑞以及Valeant制藥公司
that it accuses of putting in place obstacles that delay the development of generic medications.
名單上的公司被指控阻礙非專(zhuān)利藥發(fā)展。
The list was published following President Donald Trump's statement at a White House press conference last week,
該名單發(fā)表于唐納德·特朗普總統(tǒng)上周的白宮記者會(huì)發(fā)言之后，
where he pledged to lower prescription drug costs.
在記者會(huì)上，他承諾降低處方藥成本。
He claimed that "foreign, developed nations" are getting a "free-ride by setting drug prices at unfairly low levels,
他聲稱(chēng)“國(guó)外發(fā)達(dá)國(guó)家”利用低水平藥價(jià)不勞而獲，
leaving American patients to pay for the innovation that foreign patients enjoy."
讓美國(guó)病人為外國(guó)病人所享受的創(chuàng)新買(mǎi)單。”
譯文屬可可英語(yǔ)原創(chuàng)，未經(jīng)允許，不得轉(zhuǎn)載。
